OPKO Health, Inc. OPK.TA Stock
OPKO Health, Inc. Price Chart
OPKO Health, Inc. OPK.TA Financial and Trading Overview
OPKO Health, Inc. stock price | 439.4 ILA |
Previous Close | 559.4 ILA |
Open | 545 ILA |
Bid | 560.6 ILA x N/A |
Ask | 562 ILA x N/A |
Day's Range | 532.6 - 555.9 ILA |
52 Week Range | 369.9 - 986.5 ILA |
Volume | 663.98K ILA |
Avg. Volume | 511.49K ILA |
Market Cap | 4.15B ILA |
Beta (5Y Monthly) | 1.660563 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.91 ILA |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
OPK.TA Valuation Measures
Enterprise Value | 4.5B ILA |
Trailing P/E | N/A |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 4.545036 |
Price/Book (mrq) | 267.3307 |
Enterprise Value/Revenue | 4.936 |
Enterprise Value/EBITDA | -46.553 |
Trading Information
OPKO Health, Inc. Stock Price History
Beta (5Y Monthly) | 1.660563 |
52-Week Change | -36.33% |
S&P500 52-Week Change | 20.43% |
52 Week High | 986.5 ILA |
52 Week Low | 369.9 ILA |
50-Day Moving Average | 563.13 ILA |
200-Day Moving Average | 547.17 ILA |
OPK.TA Share Statistics
Avg. Volume (3 month) | 511.49K ILA |
Avg. Daily Volume (10-Days) | 411.19K ILA |
Shares Outstanding | 772.65M |
Float | 418.94M |
Short Ratio | N/A |
% Held by Insiders | 46.07% |
% Held by Institutions | 24.25% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | -31.91% |
Operating Margin (ttm) | -22.36% |
Gross Margin | 25.01% |
EBITDA Margin | -10.60% |
Management Effectiveness
Return on Assets (ttm) | -5.69% |
Return on Equity (ttm) | -18.39% |
Income Statement
Revenue (ttm) | 912.55M ILA |
Revenue Per Share (ttm) | 1.23 ILA |
Quarterly Revenue Growth (yoy) | -27.80% |
Gross Profit (ttm) | 214.3M ILA |
EBITDA | -96765000 ILA |
Net Income Avi to Common (ttm) | -291239008 ILA |
Diluted EPS (ttm) | -1.43 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 110.83M ILA |
Total Cash Per Share (mrq) | 0.14 ILA |
Total Debt (mrq) | 293.31M ILA |
Total Debt/Equity (mrq) | 18.9 ILA |
Current Ratio (mrq) | 1.827 |
Book Value Per Share (mrq) | 2.008 |
Cash Flow Statement
Operating Cash Flow (ttm) | -97980000 ILA |
Levered Free Cash Flow (ttm) | 226.36M ILA |
Profile of OPKO Health, Inc.
Country | Israel |
State | FL |
City | Miami |
Address | 4400 Biscayne Boulevard |
ZIP | 33137 |
Phone | 305-575-4100 |
Website | https://www.opko.com |
Industry | Diagnostics & Research |
Sector(s) | Healthcare |
Full Time Employees | 4196 |
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.
Q&A For OPKO Health, Inc. Stock
What is a current OPK.TA stock price?
OPKO Health, Inc. OPK.TA stock price today per share is 439.4 ILA.
How to purchase OPKO Health, Inc. stock?
You can buy OPK.TA shares on the Tel Aviv exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for OPKO Health, Inc.?
The stock symbol or ticker of OPKO Health, Inc. is OPK.TA.
Which industry does the OPKO Health, Inc. company belong to?
The OPKO Health, Inc. industry is Diagnostics & Research.
How many shares does OPKO Health, Inc. have in circulation?
The max supply of OPKO Health, Inc. shares is 6.97M.
What is OPKO Health, Inc. Price to Earnings Ratio (PE Ratio)?
OPKO Health, Inc. PE Ratio is now.
What was OPKO Health, Inc. earnings per share over the trailing 12 months (TTM)?
OPKO Health, Inc. EPS is -0.91 ILA over the trailing 12 months.
Which sector does the OPKO Health, Inc. company belong to?
The OPKO Health, Inc. sector is Healthcare.